Colorectal clinical trials

What is on the horizon?

Daniel Ahn, Richard M. Goldberg

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Substantial progress has been made in the treatment of colorectal cancer, where more effective therapies have led to improved outcomes in patients with advanced disease. However, the 5-year overall survival rate remains poor. Genomic sequencing has allowed us to understand that colorectal cancer is a heterogeneous disease, where tumor-specific variants affect the prognosis and outcomes in patients. This has shaped the future directions of treatment and the development of clinical trials, including the incorporation of novel targeted therapies and investigations into the role of immunotherapy in colorectal cancer.

Original languageEnglish (US)
Pages (from-to)525-531
Number of pages7
JournalFuture Oncology
Volume12
Issue number4
DOIs
StatePublished - Feb 1 2016
Externally publishedYes

Fingerprint

Clinical Trials
Colorectal Neoplasms
Therapeutics
Immunotherapy
Survival Rate
Neoplasms
Direction compound

Keywords

  • colorectal cancer
  • immunotherapy
  • next-generation sequencing
  • targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Colorectal clinical trials : What is on the horizon? / Ahn, Daniel; Goldberg, Richard M.

In: Future Oncology, Vol. 12, No. 4, 01.02.2016, p. 525-531.

Research output: Contribution to journalReview article

Ahn, Daniel ; Goldberg, Richard M. / Colorectal clinical trials : What is on the horizon?. In: Future Oncology. 2016 ; Vol. 12, No. 4. pp. 525-531.
@article{791d7b0b995e4b9ebc1e195ae35cc5ef,
title = "Colorectal clinical trials: What is on the horizon?",
abstract = "Substantial progress has been made in the treatment of colorectal cancer, where more effective therapies have led to improved outcomes in patients with advanced disease. However, the 5-year overall survival rate remains poor. Genomic sequencing has allowed us to understand that colorectal cancer is a heterogeneous disease, where tumor-specific variants affect the prognosis and outcomes in patients. This has shaped the future directions of treatment and the development of clinical trials, including the incorporation of novel targeted therapies and investigations into the role of immunotherapy in colorectal cancer.",
keywords = "colorectal cancer, immunotherapy, next-generation sequencing, targeted therapy",
author = "Daniel Ahn and Goldberg, {Richard M.}",
year = "2016",
month = "2",
day = "1",
doi = "10.2217/fon.15.327",
language = "English (US)",
volume = "12",
pages = "525--531",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Colorectal clinical trials

T2 - What is on the horizon?

AU - Ahn, Daniel

AU - Goldberg, Richard M.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Substantial progress has been made in the treatment of colorectal cancer, where more effective therapies have led to improved outcomes in patients with advanced disease. However, the 5-year overall survival rate remains poor. Genomic sequencing has allowed us to understand that colorectal cancer is a heterogeneous disease, where tumor-specific variants affect the prognosis and outcomes in patients. This has shaped the future directions of treatment and the development of clinical trials, including the incorporation of novel targeted therapies and investigations into the role of immunotherapy in colorectal cancer.

AB - Substantial progress has been made in the treatment of colorectal cancer, where more effective therapies have led to improved outcomes in patients with advanced disease. However, the 5-year overall survival rate remains poor. Genomic sequencing has allowed us to understand that colorectal cancer is a heterogeneous disease, where tumor-specific variants affect the prognosis and outcomes in patients. This has shaped the future directions of treatment and the development of clinical trials, including the incorporation of novel targeted therapies and investigations into the role of immunotherapy in colorectal cancer.

KW - colorectal cancer

KW - immunotherapy

KW - next-generation sequencing

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84957618592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957618592&partnerID=8YFLogxK

U2 - 10.2217/fon.15.327

DO - 10.2217/fon.15.327

M3 - Review article

VL - 12

SP - 525

EP - 531

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 4

ER -